NCT01476943已完成不适用
Belatacept in Renal Transplantation: Patterns of Use Analysis Using the Collaborative Transplant Study (CTS)
Bristol-Myers Squibb0 个研究点目标入组 72,392 人开始时间: 2012年3月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 72,392
- 主要终点
- The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by Cytomegalovirus (CMV) serostatus
研究概览
简要总结
The primary purpose is to describe the pattern of Belatacept use at the time of transplant and up to three years post-transplantation for all Belatacept treated patients.
详细描述
Time Perspective: Prospective design, Retrospective data collection and analysis
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who received solid organ transplantation during study period in one of the transplant centers involved in CTS
排除标准
- 未提供
结局指标
主要结局
The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by Cytomegalovirus (CMV) serostatus
时间窗: At the time of transplantation
The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by CMV serostatus
时间窗: 3 year post transplantation
次要结局
- Extent of switches to or from Belatacept within three years post transplantation, and the temporal trend in switches post regulatory approval of Belatacept(At transplantation, 12 month, 24 month and 36 month post transplantation)
- Characteristics of Belatacept users vs. Calcineurin inhibitor (CNIs) users at transplantation(At the time of transplantation)
- Characteristics of those who switch to or from Belatacept vs. those who do not switch one year post-transplant(At transplantation and 12 month post transplantation)
研究者
相似试验
已完成
不适用
Pattern Of Use Of Belatacept In US Transplant RecipientsKidney Transplantation: Transplantation, KidneyNCT01670058Bristol-Myers Squibb5,000
已完成
不适用
Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant StudyKidney TransplantationNCT01471223Bristol-Myers Squibb89
已完成
2 期
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without CorticosteroidsRenal TransplantNCT00402168Bristol-Myers Squibb173
进行中（未招募）
不适用
Belatacept Conversion Trial in Renal TransplantationRevised Protocol 02 incorporating Amendments 03 (version 1.0 dated 18-Sep-07) and 04 (version 3.0 dated 12-Oct-07)Subjects who received a kidney transplantEUCTR2005-005238-11-DEBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine orTacrolimus Regimen With or Without CorticosteroidsSubjects who received a kidney transplantEUCTR2005-005238-11-BEBristol-Myers Squibb International Corporation170